Promethera® Biosciences’ mission is to provide patients with life-saving treatmentsto reduce the need for liver transplantation.
With this in mind, the company is currently focused on advancing its cutting-edge cell therapy and antibody medicines through clinical trials in two main areas of liver disease: non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF).
The company’s lead clinical program, HepaStemTM, is derived from a patented allogeneic liver cell platform, using cells from healthy human livers that are unsuitable for transplantation. These cells are processed in a state-of-the-art GMP environment to become a treatment that can be delivered directly to patients at the point of care.
HepaStemTM has successfully concluded a phase 2a clinical trial to treat patients with ACLF. HepaStem is also the subject of an ongoing phase 2a clinical trial treating patients with NASH and has the additional potential to target liver fibrosis. The immune-modulatory and anti-fibrotic properties of HepaStemTM and the antibody Atrosimab complement each other perfectly and have potential applications across the entire spectrum of liver disease and beyond.
The Promethera Group has assembled a broad intellectual property portfolio together with an experienced international team.
Its span is truly global; from its central European Belgian headquarters and its liver sourcing and manufacturing capabilities in the US, through to the Tokyo office in Japan and antibody-based technology and drug candidates from the acquisition of Baliopharm in Switzerland.
Promethera is committed to further strengthening its research and development capabilities through internal and external development activities and strategic transactions.
Promethera’s development strategy is built around a global view to maximize the likelihood of success.
Asia (and Japan in particular) has taken a cell therapy-friendly position for years and therefore presents a big market opportunity in this area. Promethera has already benefited from this stance by attracting significant strategic and institutional investors in Japan and South Korea.
Promethera is now working to reap the maximum benefit from these initial strong ties, whilst continuing to expand its network into the wider Asian region, without neglecting the rest of the world.
Promethera plans to further improve the lives of liver patients and reduce the burden on healthcare systems by offering a two-pronged approach, focusing on both prevention and cure. Expanding its scientific efforts into larger R&D and manufacturing facilities will enable the development of new products, as well as the manufacture and clinical trials of those already in the pipeline. In addition, Promethera will utilize the knowledge of its experts to provide outreach education to schools and focus groups in order to improve awareness of the causes of liver disease and how to prevent it through healthy lifestyle choices.
Promethera® Biosciences, HepaStemTM, H2Stem® and HeparescTM are registered trademarks or trademarks of Promethera® in the Benelux, the United States and other countries. Baliopharm was acquired in 2018 and is a fully owned affiliate of Promethera.